🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Urology Times discuss the recent AUA/ SUFU amendment to the Microhematuria Guideline, including language supporting the use of Cxbladder Triage backed by Grade A Evidence from the STRATA trial. Review the article: hubs.ly/Q03dz1__0

News to share! Pacific Edge today announces tests processed at its laboratories in Q4 25 improved 6.8% on the prior quarter (Q3 25), lifted by increased adoption in the US. This included an increase in the number of US clinicians ordering Cxbladder and a lift in the number of

In late March the Pacific Edge team joined thousands of others around New Zealand to take part in the Relay for Life. The 12 hour overnight event was a chance to come together as a community, share stories and have a little fun, while fundraising in support of the Cancer

News to share! Recognition of Cxbladder’s clinical and economic value in evaluating patients presenting with hematuria is set to gain momentum at the American Urological Association’s (AUA) Annual Meeting, April 26–29 in Las Vegas. Learn more: hubs.ly/Q03jpKc50

Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines. Dr. Jay Raman and Dr. Yair Lotan sit down with Dr. Zachary Klaassen to discuss the latest developments in microhematuria evaluation. Topics include the unmet need in risk stratifying

News to share! Pacific Edge notes today that the draft ‘Gapfill’ price for Cxbladder Triage Plus have been published by the US Centers for Medicare & Medicaid Services (CMS). The proposed draft price of US$1,018.4 for the test is set to lift Pacific Edge's economics. Learn more:

May is Bladder Cancer Awareness Month, a time for those impacted by #bladdercancer to stand together and raise awareness of the disease while working to enhance its care. Learn more: hubs.ly/Q03l7vB10 #BCAM25 #BladderCancerMonth25 #BladderCancerAwarenessMonth

In late April our US team based in Hershey, Pennsylvania maintained a Pacific Edge tradition, volunteering @CocoaPacks. Cocoa Packs is a non-profit that provides food assistance and other services to enhance the wellbeing of local children - they currently provide weekly support

Cxbladder Monitor is a genomic urine test that can help ease the burden of invasive testing, reducing the frequency of cystoscopy required in those being monitored for recurrent urothelial non-muscle invasive bladder cancer. Learn more at hubs.ly/Q03lmwR70 #BCAM25

In December 2023 we surveyed 1,507 US patients being monitored for recurrent non-muscle invasive bladder cancer using BCAN's Patient Survey Network. Those surveyed reported a strong interest in non-invasive test options. Learn more: hubs.ly/Q03m9bFN0 #BCAM25

To increase awareness of our Cxbladder suite of genomic biomarker tests across Asia, the Pacific Edge team, supported by local distributors, schedule regular presentations to urological teams throughout the region. Earlier this month we presented to a team from the Sultan Idris

The Platform Reduces Unnecessary Cystoscopies. Dr. John Sfakianos discusses how Cxbladder is changing the game in microhematuria evaluation and #bladdercancer surveillance. With 99% NPV, Cxbladder Triage and Monitor tests help avoid unnecessary cystoscopies and personalize

Cxbladder Monitor is a genomic urine test that can help ease the burden of invasive testing, reducing the frequency of cystoscopy required in those being monitored for recurrent non-muscle invasive bladder cancer. Learn more at hubs.ly/Q03ngdFX0.

We're proud to co-sponsor this look into the personalized future of pathology with Jay Jhaveri from Pacific Edge Ltd. Discover how genomic testing is enhancing diagnostic accuracy and tailoring treatments. Listen now: lumeadigital.com/genomic-test-r… #PathPulse #Genomics #MedicalTech

Improving Diagnosis and Treatment of Microhematuria: Kaiser Permanente's Dr. Ronald Loo and Dr. Christopher Filson join Zach Klaassen to discuss the real-world implementation of Cxbladder Triage within the Kaiser Health System for risk stratification, including the results of a

News to share! Pacific Edge today reports a resilient financial result for the year to the end of March 2025. Improvements in the performance of the sales force, operating efficiencies and cash collection gains over the financial year have positioned the company well as it works

News to share! Pacific Edge today announces it has successfully raised NZ$16 million of new equity in a placement of new ordinary shares - NZ$1 million more than it sought. Learn more: hubs.ly/Q03qjNBg0

News to share! Pacific Edge is pleased to present its Annual Report for the year ended 31st March 2025. View the Report: hubs.ly/Q03v7k-f0

Host Diane Newman and Pacific Edge Senior Medical Director Dr. Jay Jhaveri discuss key changes incorporated into the 2025 AUA/SUFU Microhematuria Guideline and the implications for clinical practice. The updated Guideline emphasizes refined risk stratification and suggests a more

Host Diane Newman and Pacific Edge Senior Medical Director Dr. Jay Jhaveri discuss key changes incorporated into the 2025 AUA/SUFU Microhematuria Guideline and the implications for clinical practice. The updated Guideline emphasizes refined risk stratification and suggests a more